B cells imprint adoptively transferred CD8⁺ T cells with enhanced tumor immunity.

ABSTRACT:

Background

Adoptive T cell transfer (ACT) therapy improves outcomes in patients with advanced malignancies, yet many individuals relapse due to the infusion of T cells with poor function or persistence. Toll-like receptor (TLR) agonists can invigorate antitumor T cell responses when administered directly to patients, but these responses often coincide with toxicities. We posited that TLR agonists could be repurposed ex vivo to condition T cells with remarkable potency in vivo, circumventing TLR-related toxicity.

Methods

In this study we investigated how tumor-specific murine CD8⁺ T cells and human tumor infiltrating lymphocytes (TILs) are impacted when expanded ex vivo with the TLR9 agonist CpG.

Results

Herein we reveal a new way to reverse the tolerant sta

SUBMITTER: Smith AS 

PROVIDER: S-EPMC8753437 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature